Use of Metabonomics to Study Target Organ Toxicity

Metabonomics in Toxicity Assessment

Volumn , Issue , 2005, Pages 337-395

  Thomas, Craig E ^a   Holmes, Elaine ^b   Robertson, Donald G ^c  

^a ELI LILLY AND COMPANY   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872864128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14117-12     Document Type: Chapter

References (78)

1. Lee WM. Drug-induced hepatotoxicity. Med Prog 1995: 1118-1127.
2. MacGregor JT, Collins JM, Sugiyama Y, Tyson CA, Dean J, Smith L, Andersen M, Curren RD, Houston JB, Kadlubar FF, Kedderis GL, Krishnan K, Li AP, Parchment RE, Thummel K, Tomaszewski JE, Ulrich R, Vickers AEM, Wrighton SA. Forum: in vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001; 59: 17-36.
3. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Forum: mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176.
4. Beckwith-Hall BM, Nicholson JK, Nicholls AW, Foxall PJD, Lindon JC, Connor SC, Abdi M, Connelly J, Holmes E. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol 1998; 11: 260-272.
5. Nicholls AW, Holmes E, Lindon JC, Shockcor JP, Farrant RD, Haselden JN, Damment SJP, Waterfield CJ, Nicholson JK. Metabonomic investigations into hydrazine toxicity in the rat. Chem Res Toxicol 2001; 14: 975-987.
6. 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat. Mol Pharmacol 1989; 36: 398-404.
7. Timbrell JA, Waterfield CJ. Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. Adv Exp Med Biol 1996; 403: 233-245.
8. Waterfield CJ, Turton JA, Scales MD, Timbrell JA. Investigation into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats. Arch Toxicol 1993; 67: 244-254.
9. Sanins SM, Timbrell JA, Elcombe C, Nicholson JK. Hepatotoxin-induced hypertaurinuria: a proton NMR study. Arch Toxicol 1990; 64: 407-411.
10. Waters NJ, Holmes E, Williams A, Waterfield CJ, Farrant RD, Nicholson JK. NMR and pattern recognition studies on the time-related metabolic effects of a-naphthylisothiocyanate on liver, urine, and plasma in the rat: an integrative metabonomic approach. Chem Res Toxicol 2001; 14: 1401-1412.
11. Robertson DG, Reily MD, Sigler RE, Wells DF, Paterson DA, Braden TK. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci 2000; 57: 326-337.
12. Sanins SM, Timbrell JA, Elcombe C, Nicholson JK. Proton NMR spectroscopic studies on the metabolism and biochemical effects of hydrazine in vivo. Arch Toxicol 1992; 66: 489-495.
13. Sanins SM, Timbrell JA, Nicholson JK. High-resolution proton-NMR studies of metabolism and effects of hydrazine in rat. Hum Toxicol (Suppl) 1986; 5: 123.
14. Olney JW, de Gubareff T, Collins JF. Sterospecificity of the gliotoxic and anti-neurotoxic actions of alpha-aminoadipate. Neurosci Lett 1980; 19: 277-282.
15. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1997; 25: 53-60.
16. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 1990; 42: 327-354.
17. Nicholls AW, Nicholson JK, Haselden JN, Waterfield CJ. A metabonomic approach to the investigation of drug-induced phospholipidosis: an NMR spectroscopy and pattern recognition study. Biomarkers 2000; 5: 410-423.
18. Espina JR, Shockcor JP, Herron WJ, Car BD, Contel NR, Ciaccio PJ, Lindon JC, Holmes E, Nicholson JK. Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn Reson Chem 2001; 39: 559-565.
19. 13C magic angle spinning NMR spectroscopy of rat liver. Magn Reson Med 2000; 44: 201-207.
20. 1H NMR spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal Biochem 2000; 282: 16-23.
21. Waters NJ, Holmes E, Waterfield CJ, Farrant RD, Nicholson JK. NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate. Biochem Pharmacol 2002; 64: 67-77.
22. 1H NMR magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue. Magn Reson in Med 2002; 45: 781-790.
23. Holmes E, Nicholls AW, Lindon JC, Connor SC, Connelly JC, Haselden JN, Damment SJP, Spraul M, Neidig P, Nicholson JK. Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Toxicol 2000; 13: 471-478.
24. 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 1998; 11: 235-244.
25. Holmes E, Nicholson JK, Tranter G. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem Res Toxicol 2001; 14: 182-191.
26. Azmi J, Griffin JL, Antti H, Shore RF, Johansson E, Nicholson JK, Holmes E. Metabolic trajectory characterisation of xenobiotic-induced hepatotoxic lesions using statistical batch processing of NMR data. Analyst 2002; 127: 271-276.
27. Lindon JC, Nicholson JK, Everett JR. Annual Reports on NMR Spectroscopy. Vol. 38. Academic Press, 1999: 1-88.
28. Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 2000; 12(5): 289-320.
29. Le Moyec L, Pruna A, Eugene M, Bedrossian J, Idatte JM, Huneau JF, Tomé D. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation followup. Nephron 1993; 65: 433-439.
30. 1H NMR urinalysis in glomerulonephritis: a new prognostic criterion. Magn Reson Imaging 1992; 10: 127-134.
31. 1H-NMR urinalysis. Clinica Chim Acta 1993; 214: 165-173.
32. Bales JR, Nicholson JK, Sadler PJ. Two-dimensional proton nuclear magnetic resonance '‘maps’' of acetaminophen metabolites in human urine. Clin Chem 1985; 31: 757-762.
33. Powell JJ, Gartland KPR, Lombard M, Sallie R, Nicholson JK, Thompson RPH. Proton NMR spectroscopy of bile as a marker of liver function in liver-transplant patients. Clin Sci 1990; 78: 13.
34. Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog NMR Spectrosc 1989; 21: 444-501.
35. Hook JB, Smith JH. Biochemical mechanisms of nephrotoxicity. Transplantation Proceedings 17 (supplement 1): 41-50, 1985.
36. Gabriel R. Postgraduate Nephrology. 3rd ed. Butterworths, 1985.
37. Hook JB, Hewit WR. Toxic responses of the kidney. In: Klaassen CD, Amdur MO, Doull J, eds. Toxicology: The Basic Science of Poisons. New York: Macmillan, 1986: 310-329.
38. Berndt WO. Renal methods in toxicology. In: Hayes WA, ed. Principles and Methods of Toxicology. New York: Raven Press, 1982: 447-474.
39. Halman J, Fowler JSL, Price RG. Urinary enzymes, proteinuria and renal function tests in the assessment of nephrotoxicity in the rat. In: Bach PH, Lock EA, eds. Renal Heterogeneity and Target Cell Toxicity. Chichester, U.K.: Wiley, 1985: 295-298.
40. Gartland KPR, Bonner FW, Nicholson JK. Investigation into the biochemical effects of region-specific nephrotoxins. Mol Pharmacol 1989; 35: 242-250.
41. Anthony ML, Beddell CR, Lindon JC, Nicholson JK. Studies on the comparative toxicity of S-(1, 2-dichlorovinyl)-l-cysteine and 1, 1, 2-triflchloro-3, 3, 3-fluoro-1-propene in the Fischer 344 rat. Arch Toxicol 1994; 69: 99-110.
42. Holmes E, Nicholson JK, Nicholls AW, Lindon JC, Connor SC, Polley S, Connelly J. The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemometrics Intell Lab Syst 1998; 44: 245-255.
43. Tandon SK. Organ toxicity of chromium in biological and environmental aspects of chromium. In: Langard S, ed. Amsterdam: Elsevier, 1982: 209-220.
44. 1H NMR spectroscopy. Toxicol Lett 1995; 81: 15-21.
45. Griffin JL, Walker LA, Troke J, Osborn D, Shore RF, Nicholson JK. The initial pathogenesis of cadmium induced renal toxicity. FEBS Lett 2000; 478: 147-150.
46. Nanra RS. Renal effects of antipyretic analgesics. Am J Med 1983; Nov 14: 70-80.
47. Sabatini S. Analgesic-induced papillary necrosis. Semin Nephrol 1988; 8(1): 41-54.
48. Shelley JH. Pharmacological mechanisms of analgesic nephropathy. Kidney Int 1978; 13: 15-26.
49. Holmes E, Bonner FW, Nicholson JK. Comparative studies on the nephrotoxicity of 2-bromoethanamine hydrobromide in the Fischer 344 rat and the multimammate desert mouse (Mastomys natalensis). Arch Toxicol 1995; 70: 89-95.
50. Soose M, Gwinner W, Grotkamp J, Hansemann W, Stolte H. Altered renal fibronectin excretion in early adriamycin nephrosis of rats. J Pharm Exp Ther 1991; 257(1): 493-499.
51. O’Donnell MP, Michels L, Kasiske B, Raij L, Keane WF. Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med 1985; 106(1): 62-67.
52. Grond J, Koudstaal J, Elema JD. Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis. Kidney Int 1985; 27(2): 405-410.
53. Hill GS. Drug associated glomerulopathies. Toxicol Pathol 1986; 14: 37-44.
54. Cutler P, Bell DJ, Birrell HC, Connelly JC, Connor SC, Holmes E, Mitchell BC, Monte SY, Neville BA, Pickford R, Polley S, Schneider K, Skehel JM. An integrated proteomic approach to studying glomerular nephrotoxicity. Electrophoresis 1999; 20(18): 3647-3658.
55. Mazze RI, Cousins MJ, Kosek JC. Strain differences in metabolism and susceptibility to the nephrotoxic effects of methoxyfluorane in rats. J Pharmacol Exp Ther 1973; 184: 481-488.
56. Henry MA, Sweet RS, Tange JD. A new reproducible experimental model of analgesic nephropathy. J Pathol 1983; 139: 23-32.
57. Holmes E, Bonner FW, Nicholson JK. Comparative biochemical effects of low doses of mercury II chloride in the F344 rat and the multimammate mouse (Mastomys natalensis). Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996; 114(1): 7-15.
58. 1H NMR spectroscopic and histopathological studies on propyleneimine-induced renal papillary necrosis in the rat the multimammate desert mouse (Mastomys natalensis). Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997; 116(2): 125-134.
59. Rehm S, Waalkes MP. Acute cadmium chloride-induced renal toxicity in the Syrian hamster. Toxicol Appl Pharmacol 1990; 104(1): 94-105.
60. Lenz SD, Carlton WW. Diphenylamine-induced renal papillary necrosis and necrosis of the pars recta in laboratory rodents. Vet Pathol 1990; 27(3): 171-178.
61. Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 2002; 127: 549-1557.
62. Holmes E, Bonner FW, Sweatman BC, Lindon JC, Beddell CR, Rahr E, Nicholson JK. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury (II) chloride and 2-bromoethanamine. Mol Pharmacol 1992; 42: 922-930.
63. Murgatroyd LB, Pickford RJ, Smith IK, Wilson ID, Middleton BJ. 1H NMR spectroscopy as a means of monitoring nephrotoxicity as exemplified by studies with cephaloridine. Hum Exp Toxicol 1992; 11(1): 35-41.
64. Gartland KP, Anthony ML, Beddell CR, Lindon JC, Nicholson JK. Proton NMR studies on the effects of uranyl nitrate on the biochemical composition of rat urine and plasma. J Pharm Biomed Anal 1990; 8(8-12): 951-954.
65. Joseph EC, Jones HB, Kerns WD. Characterization of coronary arterial lesions in the dog following administration of SKandF 95654, a phosphodiesterase III inhibitor. Toxicol Pathol 1996; 24: 429-435.
66. Larson JL, Pino MV, Geiger LE, Simeone CR. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 1996; 78: 44-49.
67. Albassam MA, Metz AL, Gragtmans NJ, King LM, Macallum GE, Hallak H, McGuire EJ. Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. Toxicol Pathol 1999; 27: 156-164.
68. Albassam MA, Metz AL, Potoczak RE, Gallagher KP, Haleen S, Hallak H, McGuire EJ. Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist. Toxicol Pathol 2001; 29: 277-284.
69. Metz AL, Dominick MA, Suchanek G, Gough AW. Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol Pathol 1991; 19: 98-107.
70. Kerns WD, Arena E, Macia RA, Bugelski PJ, Matthews WD, Morgan DG. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol Pathol 1989; 17: 203-213.
71. Mesfin GM, Robinson FG, Higgins MJ, Zhong WZ, DuCharme DW. The pharmacologic basis of the cardiovascular toxicity of minoxidil in the dog. Toxicol Pathol 1995; 23: 498-506.
72. Robertson DG, Reily DR, Albassam M, Dethloff LA. Metabonomic assessment of vasculitis on rats. Cardiovasc Toxicol 2001; 1: 7-9.
73. Dethloff LA, Pegg DG, Metz AL. Preclinical toxicity studies of the phosphodiesterase IV inhibitor CI-1018 in rats. Toxicol Sci 1999; 48(1S): 1502a.
74. Slim RM, Robertson DG, Albassam M, Reily MD, Robosky L, Dethloff LA. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced mesenteric vascular lesions in rats. Toxicol Appl Pharmacol 2002; 183: 108-116.
75. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol 2000; 75: S9-S19.
76. Igarashi H, Hatake K, Shiraishi H, Samada K, Tomizuka H, Momoi MY. Elevated serum levels of macrophage colonystimulating factor in patients with Kawasaki disease complicated by cardiac lesions. Clin Exp Rheumatol 2001; 19: 751-756.
77. Merkel, PA. Drug-induced vasculitis. Rheum Dis Clin North Am 2001; 27: 849-862.
78. Robertson DG, Reily MD, Albassam M, Dethloff LA, Wells DF, Braden TK. Metabonomic assessment of drug-induced vasculitis in rats. Toxicol Sci 2001; 60(1S): 375.